(ABI) Abraxis Bio gets FDA approval for Amphicillin Injection.
(AGN) Allergan up on Cramer from Mad Money.
(AH) Armor Holdings wins another $53 million order for components.
(ARNA) Arena filed to sell 8M shares of stock.
(CHS) Chico’s $0.24 EPS vs $0.24e.
(COF) Capitol One noted as a creditcard winner on Cramer’s Mad Money.
(COMS) 3Com paid $882 million to buyout the rest of the interest in its Huawei joint venture.
(CPC) Central Parking hired Blackstone to enhance value.
(DBRN) Dress Barn $0.40 EPS vs $0.37e.
(DVAX) Dynavax noted statistically significantresults in phase III hepatitis B vaccine.
(FLR) Fluor won management pact over a $2.2 Billion Saudi Construction pact.
(JPM) JPMOrgan sold its Amaranth stake to Citadel for $725M.
(LNUX) VA Linux $0.00/R$10.3M vs $0.01/$10.25M(e)
(OPSW) Opsware $0.01 EPS vs $0.00e.
(PFE) Pfizer said it will trim its sales force by 20%.
(PFG) Principal Financial approved $250M share buyback.
PKD has a 3.8M share secondary.
(SGMO) Sangamo started phase II studies for diabetic neuropathy.
(SPSN) Spansion’s stake held by AMD was trimmed last week to 21%.
(SSS) Sovran has a 2M share secondary.
(THQI) THQ signed Miocrosoft pact for retail distribution.
(TIF) Tiffany’s $0.21 EPS vs $0.16e.
(TUG) Maritrans buyout completed.
(WGOV) Wooward Governor in supply pact with GE.
(WPSC) Whheling Pittsburgh lowered guidance.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on 247wallst.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.